GMP IPO Watch
ICICI Prudential Nifty Pharma Index Fund
Direct Plan · Growth · ICICI Prudential Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +2.99% | +3.19% | 174 of 283 |
| 1M | +3.84% | +2.85% | 92 of 283 |
| 3M | +2.72% | -2.37% | 4 of 283 |
| 6M | +16.58% | +1.56% | 3 of 278 |
| YTD | +20.97% | -0.86% | 1 of 283 |
| 1Y | +22.53% | -0.15% | 1 of 263 |
| 2Y | +10.15% | +2.58% | 6 of 193 |
| 3Y | +22.50% | +9.71% | 3 of 142 |
| INCEPTION | +21.44% | — | — |
Ranked among: Other Scheme - Index Funds.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +5.79% | +25.95% | -13.72% | 75% | 31% |
| 6M | +11.97% | +33.19% | -15.92% | 84% | 36% |
| 1Y | +23.40% | +63.13% | -8.44% | 90% | 42% |
| 2Y | +19.15% | +36.46% | +4.49% | 100% | 46% |
| 3Y | +21.97% | +26.87% | +18.87% | 100% | 48% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity99.93%
- Debt0.00%
- Cash0.06%
- Other0.01%
Market Cap Split
- Large Cap46.31%
- Mid Cap46.07%
- Small Cap7.55%
- Others0.07%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 37.33 | 23.30 |
| P/B | 5.12 | 3.81 |
| Price / Sales | 5.63 | 3.27 |
| Price / Cash Flow | 29.45 | 17.22 |
| Dividend Yield (%) | 0.68 | 1.63 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 19.50% | -1.26% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 11.97% | +0.09% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 7.82% | +0.46% |
| Cipla | Pharmaceuticals & Biotechnology | 7.68% | -0.15% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 7.62% | +0.67% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 7.16% | -0.18% |
| Lupin | Pharmaceuticals & Biotechnology | 5.00% | -0.25% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 4.68% | -0.01% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.56% | -0.13% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 3.16% | +0.08% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.92% | +0.05% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 2.88% | +0.18% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.71% | +0.00% |
| Biocon | Pharmaceuticals & Biotechnology | 2.62% | -0.28% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 2.34% | +0.07% |
View all 22 holdings
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 2.14% | +0.15% |
| Wockhardt | Pharmaceuticals & Biotechnology | 1.77% | +0.23% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 1.67% | +0.17% |
| TREPS | Reverse Repo / TREPS | 1.50% | — |
| Abbott | Pharmaceuticals & Biotechnology | 1.43% | +0.12% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 1.30% | -0.02% |
| Net Current Assets | Net Current Assets | -1.44% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 14.12 | 12.38 | High Volatility |
| 3Y | 15.17 | 10.25 | High Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.29 | -0.51 | Above Average |
| 3Y | 1.05 | 0.26 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 2.43 | 12.56 | Below Average |
| 3Y | 2.14 | 8.16 | Below Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Tracking Difference
Versus Nifty Pharma TRI, as of Sep 2026.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund
Direct Plan · Growth
|
+20.88% | +21.50% | +14.91% | +16.74% |
|
Tata Nifty Capital Markets Index Fund
Direct Plan · Growth Option
|
+19.89% | — | — | +21.71% |
|
Motilal Oswal Nifty Capital Market Index Fund
Regular Plan · Growth
|
+19.31% | — | — | +16.06% |
|
Motilal Oswal S&P 500 Index Fund
Direct Plan · GROWTH
|
+18.19% | +25.74% | +16.20% | +20.46% |
|
Tata Nifty MidSmall Healthcare Index Fund
Regular Plan · IDCW Payout Option
|
+17.24% | — | — | +17.73% |
|
Motilal Oswal Nifty MidSmall Healthcare Index Fund
Regular Plan · Growth
|
+17.19% | — | — | +11.55% |
|
ICICI Prudential NASDAQ 100 Index Fund
Regular Plan · Growth
|
+15.21% | +27.99% | +16.74% | +17.49% |
|
Bandhan BSE Healthcare Index Fund
Regular Plan · Growth
|
+13.22% | — | — | +7.26% |
|
Motilal Oswal Nifty India Defence Index Fund
Regular Plan · Growth
|
+13.06% | — | — | +4.19% |
|
DSP Nifty Healthcare Index Fund
Regular Plan · Growth
|
+12.65% | — | — | +12.61% |
More From ICICI Prudential Asset Management Company Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
ICICI Prudential Strategic Metal and Energy Equity Fund of Fund
Direct Plan · IDCW
|
+54.73% | +34.44% | — | +28.69% |
| ICICI PRUDENTIAL SILVER ETF | +26.35% | +36.57% | — | +24.10% |
|
ICICI Prudential Silver ETF FOF
Direct Plan · IDCW
|
+25.48% | +35.58% | — | +24.36% |
|
ICICI Prudential Global Stable Equity Fund (FOF)
Direct Plan · Growth
|
+21.49% | +15.76% | +11.03% | +10.51% |
|
ICICI Prudential US Bluechip Equity Fund
Direct Plan · IDCW
|
+21.29% | +19.31% | +13.10% | +16.61% |
| ICICI Prudential Nifty Metal ETF | +19.46% | — | — | +16.41% |
|
ICICI Prudential Gold ETF FOF
Direct Plan · Growth
|
+17.38% | +30.99% | +23.18% | +10.56% |
| ICICI Prudential Gold ETF | +16.94% | +31.16% | +23.37% | +12.02% |
|
ICICI Prudential NASDAQ 100 Index Fund
Direct Plan · Growth
|
+15.77% | +28.57% | +17.30% | +18.04% |
| ICICI Prudential Nifty Healthcare ETF | +13.50% | +21.36% | +14.63% | +14.03% |
About This Scheme
Investment Objective
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Stated Asset Allocation
• Equity and Equity related securities of companies constituting the underlying index (Nifty Pharma Index) = 95% - 100% • Money Market instruments including TREPs* and Units of debt schemes# = 0% - 5%
Exit Load
Nil
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.